在 11 月 12 日晚，A股已上市的创新药企 百利天恒突发公告：决定延迟其 H 股全球发售及挂牌计划。按照此前规划，公司原定于 11 月 17 日在港交所挂牌交易，成为典型“A ＋ H”双市场布局的创新药企业。公司公告中给出的理由是“鉴于现行市况”。然而，在这一看似简短的原因背后，或许正反映出当前创新药企在资本狂热与临床价值之间的艰难平衡。【01 招股急刹车：市场疑虑与深层因素】百利天恒此次 H...
Source Link在 11 月 12 日晚，A股已上市的创新药企 百利天恒突发公告：决定延迟其 H 股全球发售及挂牌计划。按照此前规划，公司原定于 11 月 17 日在港交所挂牌交易，成为典型“A ＋ H”双市场布局的创新药企业。公司公告中给出的理由是“鉴于现行市况”。然而，在这一看似简短的原因背后，或许正反映出当前创新药企在资本狂热与临床价值之间的艰难平衡。【01 招股急刹车：市场疑虑与深层因素】百利天恒此次 H...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.